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Historically the Brazilian pharmaceutical industry went
through different phases, which reflected, at least in
part, national economic stages. Until the last decade
Brazil was dominated by foreign pharmaceutical indus-
try. This has been changing as some national companies,
supported by the federal government, have started
developing new molecules derived from academic
research, as well as producing drugs whose patents have
expired. Biopharmaceuticals are extremely sophisticated
drugs, synthesized by cell manipulation and designed to
treat complex diseases. This change in the industry’s
attitude pointed to new requirements, well known in
developed countries, such as greater regulatory involve-
ment, training people, structuring specialized centers,
among others. Naturally, some centers have emerged in
the last two decades and these changes have brought a
new impetus to preclinical studies laboratories. This fact
was evidenced by Ordinance No. 8 (of 16th June 2011),
which established the Working Group for the articula-
tion of Reference Centers in Pharmacology. Further-
more, other actions were also reinforced, such as the
introduction of Good Laboratory Practice (GLP) by
INMETRO, the search of bilateral recognition for toxi-
cology studies between Brazil and OECD, the release of
the Guidelines for nonclinical security studies required
for drug development by ANVISA, and the establish-
ment of the regulatory agency for animal facilities (Con-
selho Nacional de Controle de Experimentação Animal -
CONCEA), created in 2008 with the approval of the
“Arouca” Law. ANVISA, however, still has a timid per-
formance in pre-clinical studies. It is based on the law
of September 23, 1976, which addresses the need to
prove the drug efficacy and safety, and the RDC No 136
of May 29, 2003, which mentions the need for reporting
preclinical trials results for a new drug to be registered.
At this point, it should be emphasized that there is a
long way to go, considering that for risk and safety
assessment of new drugs (especially as it relates to
Biopharmaceuticals) there is often a need to apply two
or three concomitant guidelines including EMEA, ICH
and OECD for designing a study plan. This practice also
brings with it the need for training people in the scope
of quality, as well as management of this practice.
Depending on their size and strategy, multinational
pharmaceutical companies may conduct extensive in-
house research or seek to license promising drugs from
academia, other pharmaceuticals, or biotechnology com-
panies. The Brazilian academic institutions have sub-
stantial research and publications related to new
molecules, as well as new therapeutic applications for
known molecules. However the practice of partnerships
between the academia and industry is quite new in our
country. Few industries have learned this path as a
route to innovation, but those who have already tried it,
are emerging as innovative companies obtaining their
first products.
Following the development of new drugs, preclinical
studies stay in between the academic research and the
clinical trials, to determine the safe use interval between
the effectiveness and the therapeutic regimen. Thus, it is
not uncommon that a long and laborious period is
devoted to this phase, since the data obtained in the
development of protocols may require changes in doses,
in the molecule, in the pharmaceutical formulation or in
the vehicle. Thus, the need for a well trained staff, work-
ing as a team, with knowledge of regulatory compliance
practices (GLP) and good relationships with the industry
that owns the investigated molecule is a must. A solid
development requires the participation of leading scien-
tists in each one of the areas involved in the discussion
of the data obtained. These professionals are veterinar-
ians, professionals of veterinary clinical analysis lab,
veterinary pathologists with training in toxicology, as
well as the toxicologist as the director of studies in
accordance with BLP. Correct decisions about the
course of development of the drugs are based on such
discussions, which should also include toxicologists
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from the industry staff, who must have the ability to
understand the importance of data and guide the neces-
sary changes. The interaction between the laboratories
that develop the preclinical protocols and the industry,
tends to promote common learning, generating aggrega-
tion of skills to the research area and the overall develop-
ment of the pharmaceutical industry. It is important to
note in this regard that most Brazilian companies are still
in this learning process and have not yet internalized all
the requirements discussed above. This is particularly so
for biopharmaceuticals, for which only recently ANVISA
has opened applications for registration.
The gradual and progressive structuring of the area of
preclinical trials in Brazil, according to the standards
described above, favors the expansion and strengthening
of the Brazilian pharmaceutical industry, opening oppor-
tunities to external marketing of our products in addi-
tion to supplying important basic needs to our health
system. Regarding preclinical studies, in 2008 the FDA
approved the first preclinical test done outside devel-
oped countries. The study conducted by Bridge Labora-
tories was held in China following BPLs. This approval
opens an opportunity to start the process of building
credibility of institutions located in developing countries.
This may include Brazil, considering the progress of its
national industry, the number of compounds in the
business pipeline, the increased funding in R&D and the
degree of diversification of products under development.
It is important to emphasize that preclinical testing by
GLP is an eliminatory criterion, and this set of rules is
fundamental for the quality assessment of the safety and
efficacy of new drugs, not only to ANVISA, but to other
countries as well, allowing the inclusion of Brazil in the
international scene. Finally, it is imperative that INME-
TRO, ANVISA and RENAMA (National Network of
Alternative Methods) go towards harmonization to the
international laws. These advances must occur concur-
rently between pharmaceutical companies, preclinical
service providers and regulatory agencies.
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